Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st March 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.3m.
Anatara Lifesciences Ltd (ASX:ANR) provides an update on the impact to the Company of the COVID-19 pandemic.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement.
The Directors present their report together with the financial statements, on the consolidated entity (referred to hereafter as 'the Group'), consisting of Cann Global Limited ('the Company') and the entities it controlled at the end of or during the half-year ended 31 December 2019.
Anatara Lifesciences Ltd (ASX:ANR) present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2019.
Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.
Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has agreed to place 34 million new fully paid ordinary shares (New Shares) to institutional and sophisticated investors led by New York-based Sea Otter Global.
